Evidence map›Paper›PMID 32330298›Full record

ArticleJournal of neurochemistry2020

Cathepsin B inhibition blocks neurite outgrowth in cultured neurons by regulating lysosomal trafficking and remodeling.

Muzhou Jiang, Jie Meng, Fan Zeng, Hong Qing, Gregory Hook, Vivian Hook, Zhou Wu, Junjun Ni

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Cathepsin B modulates microglial migration and phagocytosis of amyloid β in Alzheimer's disease through PI3K-Akt signaling.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Cathepsin B p.Gly284Val Variant in Parkinson's Disease Pathogenesis.International journal of molecular sciences · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Muscle-to-Brain Signaling Via Myokines and Myometabolites.Brain plasticity (Amsterdam, Netherlands) · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Muzhou JiangDepartment of Aging Science and Pharmacology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.ORCID 0000-0003-4877-3603
Jie MengDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0003-0184-4136
Fan ZengDepartment of Aging Science and Pharmacology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-4016-7302
Hong QingKey Laboratory of Molecular Medicine and Biotherapy in the Ministry of Industry and Information Technology, Department of Biology, School of Life Science, Beijing Institute of Technology, Beijing, China.
Gregory HookAmerican Life Science Pharmaceuticals, La Jolla, CA, USA.
Vivian HookSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, CA, USA.
Zhou WuDepartment of Aging Science and Pharmacology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.ORCID 0000-0002-4910-9037
Junjun NiDepartment of Aging Science and Pharmacology, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.ORCID 0000-0001-8486-8146
Kyushu University · JPBeijing Institute of Technology · CNAmerican Life Science Pharmaceuticals (United States) · USSichuan University · CNUniversity of Montana · US

Funding

Development of Molecular Probe Inhibitors of Pathogenic, Cytosolic Cathespin B in Traumatic Brain Injury and Alzheimers Disease NeurodegenerationR01NS109075 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HOOK, VIVIAN Y. H · 2019 to 2023
$3.7M
Development of a commercialization plan for traumatic brain injury therapeuticsR41NS110147 · NINDS · AMERICAN LIFE SCIENCE PHARMACEUTICALS · PI HOOK, GREGORY R · 2018 to 2019
$623k
NINDS NIH HHS R01 NS109075NINDS NIH HHS R41 NS110147
6 · The paper itself

Abstract

Lysosomes are known to mediate neurite outgrowth in neurons. However, the principal lysosomal molecule controlling that outgrowth is unclear. We studied primary mouse neurons in vitro and found that they naturally develop neurite outgrowths over time and as they did so the lysosomal cysteine protease cathepsin B (CTSB) mRNA levels dramatically increased. Surprisingly, we found that treating those neurons with CA-074Me, which inhibits CTSB, prevented neurites. As that compound also inhibits another protease, we evaluated a N2a neuronal cell line in which the CTSB gene was deleted (CTSB knockout, KO) using CRISPR technology and induced their neurite outgrowth by treatment with retinoic acid. We found that CTSB KO N2a cells failed to produce neurite outgrowths but the wild-type (WT) did. CA-074Me is a cell permeable prodrug of CA-074, which is cell impermeable and a specific CTSB inhibitor. Neurite outgrowth was and was not suppressed in WT N2a cells treated with CA-074Me and CA-074, respectively. Lysosome-associated membrane glycoprotein 2-positive lysosomes traffic to the plasma cell membrane in WT but not in CTSB KO N

Indexed as

AnimalsAnimals, NewbornCathepsin BCell Line, TumorCells, CulturedCysteine ProteasesFemaleGene Knockout TechniquesLysosomesMaleMiceMice, Inbred C57BLNeocortexNeuritesNeuronsProtein TransportCathepsin BCtsb protein, mouseCysteine ProteasesCathepsin BLysosomesNeurite outgrowthNeuron

Identifiers

PMID32330298
PMCPMC7581626
OpenAlexW3018120341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.